Unknown

Dataset Information

0

CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer.

ABSTRACT:

SUBMITTER: Remon J 

PROVIDER: S-EPMC8797323 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer.

Remon Jordi J   Collazo Ana A   Jimenez Beatriz B  

Translational cancer research 20200401 4

Similar Datasets

Unknown First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.
| S-EPMC8864530 | biostudies-literature
Unknown Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.
| S-EPMC10774956 | biostudies-literature
Unknown First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
| S-EPMC10542710 | biostudies-literature
Unknown Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
| S-EPMC9937094 | biostudies-literature
Unknown Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
| S-EPMC5476941 | biostudies-literature
Unknown First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
| S-EPMC6494267 | biostudies-literature
Unknown First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
| S-EPMC8956544 | biostudies-literature
Unknown HR+/HER2- Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review.
| S-EPMC10297170 | biostudies-literature
Unknown First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
| S-EPMC8493593 | biostudies-literature
Unknown Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer.
| S-EPMC10278740 | biostudies-literature